Close Menu

NEW YORK — Quotient Limited said on Monday that it has received Emergency Use Authorization (EUA) from the US Food and Drug Administration for a SARS-CoV-2 antibody test designed to run on the company's MosaiQ platform for blood grouping and transfusion-transmitted infection screening.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.